(CNN) — In an analysis released Wednesday, the US Food and Drug Administration said the Johnson & Johnson COVID-19 vaccine has met the requirements for emergency use authorization.
The efficacy of the Johnson & Johnson vaccine against moderate to severe/critical Covid-19 across all geographic areas was 66.9% at least 14 days after the single dose vaccination and 66.1% at least 28 days after vaccination, a new analysis meant to brief the FDA’s Vaccines and Related Biological Products Advisory Committee said.READ MORE: Atmospheric River: North Bay Water Officials Wait & See On Easing Restrictions After Major Storm
“There were no specific safety concerns identified in subgroup analyses by age, race, ethnicity, medical comorbidities, or prior SARS-CoV-2 infection,” the analysis said.READ MORE: UPDATE: Residents in Santa Cruz Mountain Dig Out From Storm Debris
In a briefing document, the FDA said that it has reviewed the data for the vaccine and has determined that it is “consistent with the recommendations set forth in FDA’s guidance Emergency Use Authorization for Vaccines to Prevent COVID-19.”MORE NEWS: UPDATE: San Francisco Public Works Crews Scramble to Clean Up After Historic Storm
An independent group of FDA advisers, the Vaccines and related Biological Products Advisory Committee, will consider the documents and make a recommendation about whether the COVID-19 vaccination should be authorized. The committee meets on Friday.